<DOC>
	<DOCNO>NCT00723749</DOCNO>
	<brief_summary>The aim post marketing surveillance study investigate retention rate 12 month drug dependence treatment SUBOXONE® ( buprenorphine plus naloxone ) opioid dependent patient real life condition .</brief_summary>
	<brief_title>Treatment Opioid Dependent Patients With Suboxone : Acceptability &amp; Safety Data From Real Life Scenario ( Study P05603 )</brief_title>
	<detailed_description>Nonprobability sample do invitation volunteer intention document 4 5 patient per physician substitution therapy Suboxone plan indicate .</detailed_description>
	<mesh_term>Opioid-Related Disorders</mesh_term>
	<mesh_term>Substance-Related Disorders</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<mesh_term>Buprenorphine , Naloxone Drug Combination</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>Both adult adolescent patient 15 year age consent addiction treatment opioid dependence within scope medical , social psychotherapeutic measure include . Therapeutic indication contraindication SUBOXONE® must observe select patient . In accordance product information , take consideration patient suffer simultaneously acute alcoholism , delirium tremens , severe respiratory severe liver insufficiency .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Suboxone</keyword>
	<keyword>Subutex</keyword>
	<keyword>Buprenorphine</keyword>
	<keyword>Naloxone</keyword>
</DOC>